24-Apr-2026
Globe Newswire (Tue, 21-Apr 4:40 PM ET)
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
Globe Newswire (Thu, 16-Apr 9:01 AM ET)
PRNewswire (Wed, 15-Apr 9:00 AM ET)
Globe Newswire (Wed, 8-Apr 10:31 AM ET)
PRNewswire (Thu, 19-Mar 8:30 AM ET)
Market Chameleon (Tue, 3-Mar 4:25 AM ET)
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Theravance Biopharma - trades on the NASDAQ stock market under the symbol TBPH.
As of April 24, 2026, TBPH stock price climbed to $16.46 with 265,251 million shares trading.
TBPH has a beta of 1.47, meaning it tends to be more sensitive to market movements. TBPH has a correlation of 0.13 to the broad based SPY ETF.
TBPH has a market cap of $847.57 million. This is considered a Small Cap stock.
Last quarter Theravance Biopharma - reported $46 million in Revenue and $1.15 earnings per share. This fell short of revenue expectation by $-8 million and exceeded earnings estimates by $.81.
In the last 3 years, TBPH traded as high as $21.03 and as low as $7.44.
The top ETF exchange traded funds that TBPH belongs to (by Net Assets): VTI, IWM, VXF, PBE, IBB.
TBPH has outperformed the market in the last year with a return of +72.5%, while the SPY ETF gained +31.9%. However, in the most recent history, TBPH shares have underperformed the stock market with its stock returning -18.7% in the last 3 month period and +0.7% for the last 2 week period, while SPY has returned +3.8% and +5.1%, respectively.
TBPH support price is $15.94 and resistance is $16.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TBPH shares will trade within this expected range on the day.